Aliskiren versus ramipril in hypertension

Therapeutic Advances in Cardiovascular Disease

Volumn 4, Issue 3, 2010, Pages 193-200

  Verdecchia, Paolo ^a   Angeli, Fabio ^a   Mazzotta, Giovanni ^a   Martire, Paola ^a   Garofoli, Marta ^a   Gentile, Giorgio ^b   Reboldi, Gianpaolo ^b  

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Aliskiren; Angiotensin converting enzyme inhibitors; Hypertension; Ramipril; Renin angiotensin system

Indexed keywords

ALISKIREN; ANGIOTENSIN II; PLACEBO; RAMIPRIL;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; DRUG EFFICACY; HUMAN; HYPERTENSION; MONOTHERAPY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTOLIC BLOOD PRESSURE;

EID: 77952922115     PISSN: 17539447     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753944710369682     Document Type: Article

References (38)

1. Alderman, M.H., Madhavan, S., Ooi, W.L., Cohen, H., Sealey, J.E. and Laragh, J.H. ( 1991) Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 324: 1098-1104.
2. Andersen, K., Weinberger, M.H., Egan, B., Constance, C.M., Ali, M.A., Jin, J. et al. (2008) Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 26: 589-599.
3. Andersen, K., Weinberger, M.H., Egan, B., Constance, C.M., Ali, M.A., Jin, J. et al. (2007) Aliskiren-based therapy lowers blood pressure more effectively than ramipril-based therapy in patients with hypertension: a 6-month, randomized, double-blind trial. J Am Coll Cardiol 49 (Suppl A): A371.
4. Brown, M.J. ( 2008) Aliskiren. Circulation 118: 773-784.
5. Campbell, D.J., Woodward, M., Chalmers, J.P., Colman, S.A., Jenkins, A.J., Kemp, B.E. et al. (2005) Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease. Circulation 112: 110-116.
6. Carter, B.L., Ernst, M.E. and Cohen, J.D. ( 2004) Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 43: 4-9.
7. Cohen, J. ( 1988) Statistical Power Analysis for the Behavioural Sciences, 2nd edn, Lawrence Erlbaum Associates : Hillsdale, NJ.
8. Duprez, D.A., Davis, P. and Botha, J. ( 2008) The AGELESS study: The effect of aliskiren versus ramipril alone or in combination with hydrochlorothiazide and amlodipine in patients 65 years of age with systolic hypertension (abstract 4423). Circulation 118: 886-887.
9. Duprez, D.A., Munger, M.A., Botha, J., Keefe, D.L. and Charney, A.N. ( 2009) Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. J Hum Hypertens. Advance online publication 24 December 2009; doi: 10.1038/jhh.2009.107.
10. Gradman, A.H., Schmieder, R.E., Lins, R.L., Nussberger, J., Chiang, Y. and Bedigian, M.P. ( 2005) Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 111: 1012-1018.
11. Gregoire, G., Derderian, F. and Le Lorier, J. ( 1995) Selecting the language of the publications included in a meta-analysis: is there a Tower of Babel bias? J Clin Epidemiol 48: 159-163.
12. Haynes, R.B., Wilczynski, N., McKibbon, K.A., Walker, C.J. and Sinclair, J.C. ( 1994) Developing optimal search strategies for detecting clinically sound studies in MEDLINE. J Am Med Inform Assoc 1: 447-458.
13. Julius, S., Kjeldsen, S.E., Weber, M., Brunner, H.R., Ekman, S., Hansson, L. et al. (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363: 2022-2031.
14. McAuley, L., Pham, B., Tugwell, P. and Moher, D. ( 2000) Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses? Lancet 356: 1228-1231.
15. McMurray, J.J.V., Pitt, B., Latini, R., Maggioni, A.P., Solomon, S.D., Keefe, D.L. et al. (2008) Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 1: 17-24.
16. Meisel, S., Shamiss, A. and Rosenthal, T. ( 1994) Clinical pharmacokinetics of ramipril. Clin Pharmacokinet 26: 7-15.
17. Oparil, S., Yarows, S.A., Patel, S., Fang, H., Zhang, J. and Satlin, A. ( 2007) Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 370: 221-229.
18. Palatini, P., Jung, W., Shlyakhto, E., Botha, J., Bush, C. and Keefe, D.L. (2010) Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. J Hum Hypertens 24: 93-103.
19. Parving, H.H., Persson, F., Lewis, J.B., Lewis, E.J. and Hollenberg, N.K. ( 2008) Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358: 2433-2446.
20. Sever, P.S., Gradman, A.H. and Azizi, M. (2009) Managing cardiovascular and renal risk: the potential of direct renin inhibition. J Renin Angiotensin Aldosterone Syst 10: 65-76.
21. Solomon, S.D. ( 2008) Effect of the direct renin inhibitor aliskiren, either alone or in combination with losartan, compared to losartan, on left ventricular mass in patients with hypertension and left ventricular hypertrophy: the Aliskiren Left Ventricular Assessment of Hypertrophy (ALLAY) trial. In: Proceedings of the SCAI-ACC i 2 Summit / American College of Cardiology Annual Scientific Session, Chicago, IL, March-April 2008.
22. Staessen, J.A., Li, Y. and Richart, T. ( 2006) Oral renin inhibitors. Lancet 368: 1449-1456.
23. Staessen, J.A., Wang, J.G. and Thijs, L. ( 2001) Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 358: 1305-1315.
24. Stanton, A., Jensen, C., Nussberger, J. and O'Brien, E. ( 2003) Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 42: 1137-1143.
25. Strasser, R.H., Puig, J.G., Farsang, C., Croket, M., Li, J. and van Ingen, H. ( 2007) A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. J Hum Hypertens 21: 780-787.
26. Turnbull, F. ( 2003) Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362: 1527-1535.
27. Urata, H., Kinoshita, A., Misono, K.S., Bumpus, F.M. and Husain, A. ( 1990) Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 265: 22348-22357.
28. Uresin, Y., Taylor, A., Kilo, C., Tschöpe, D., Santonastaso, M., Ibram, G. et al. (2006) Aliskiren, a novel renin inhibitor, has greater BP lowering than ramipril and additional BP lowering when combined with ramipril in patients with diabetes and hypertension. J Hypertens 24(Suppl 4): 82.
29. Uresin, Y., Taylor, A.A., Kilo, C., Tschope, D., Santonastaso, M., Ibram, G. et al. (2007) Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 8: 190-198.
30. van de Wal, R.M., Plokker, H.W., Lok, D.J., Boomsma, F., van der Horst, F.A., van Veldhuisen, D.J. et al. (2006) Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol 106: 367-372.
31. Verdecchia, P., Angeli, F., Mazzotta, G., Gentile, G. and Reboldi, G. ( 2008) The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. Vasc Health Risk Manag 4: 971-981.
32. Verdecchia, P., Staessen, J.A., Angeli, F., de Simone, G., Achilli, A., Ganau, A. et al. (2009) Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial Lancet 374: 525-533.
33. Villamil, A., Chrysant, S.G., Calhoun, D., Schober, B., Hsu, H., Matrisciano-Dimichino, L. et al. (2007) Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 25: 217-226.
34. Vrijens, B., Vincze, G., Kristanto, P., Urquhart, J. and Burnier, M. ( 2008) Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 336: 1114-1117.
35. Weir, M., Bush, C., Zhang, J., Keefe, D. and Satlin, A. ( 2006) Antihypertensive efficacy and safety of the oral renin inhibitor aliskiren in patients with hypertension: a pooled analysis. Eur Heart J 27(Suppl): 299.
36. Wood, J.M., Schnell, C.R., Cumin, F., Menard, J. and Webb, R.L. ( 2005) Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens 23: 417-426.
37. Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R. and Dagenais, G. ( 2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342: 145-153.
38. Zhao, C., Vaidyanathan, S., Yeh, C.M., Maboudian, M. and Armin Dieterich, H. ( 2006) Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet 45: 1125-1134.